Fort Myers, FL, United States

NeoGenomics Laboratories

www.neogenomics.com
Fort Myers, FL, United States
SEARCH FILTERS
Time filter
Source Type

Patent
NeoGenomics Laboratories | Date: 2016-08-17

A method for predicting resistance to BTK inhibitors in patients with chronic lymphocytic leukemia (CLL) enhances the sensitivity of Sanger sequencing and NGS by using wild-type blocking of genes that are relevant for detecting resistance to ibrutinib. Further enhancement of sensitivity can be achieved by using cell-free DNA.


Compositions and fragment length analysis methods are provided for detecting CALR mutations and determining tumor load in patients with myeloproliferative neoplasms. According to the invention, cell-free DNA in peripheral blood plasma or serum from a patient suspected of having MPN is tested for CALR mutations and to determine tumor load by using fragment length analysis which can be further combined with direct bidirectional sequencing. Utilizing fragment length analysis (FLA) provides a more efficient approach for the quantification of allele burden compared to traditional Sanger Sequencing.


Patent
NeoGenomics Laboratories | Date: 2015-12-10

An automated method and system are provided for receiving an input of flow cytometry data and analyzing the data using a hierarchical arrangement of analytical elements, each of which utilizes a support vector machine to automatically classify the data into different subpopulations to recognize a pattern within the data. The pattern may be used to generate a diagnostic prediction for a patient or to identify patterns within samples collected from multiple subjects.


Patent
NeoGenomics Laboratories | Date: 2013-12-03

The present invention relates to a method for screening, predicting or prognosing esophageal adenocarcinoma/high grade dysplasia in a subject.


Methods are provided for treating, managing, diagnosing and monitoring myelodysplastic syndrome and other hematologic malignancies. These methods comprise the next generation sequencing analysis conducted on cell-free DNA from peripheral blood plasma or serum.


Compositions and fragment length analysis methods are provided for detecting CALR mutations and determining tumor load in patients with myeloproliferative neoplasms.


Patent
NeoGenomics Laboratories | Date: 2016-07-01

A method for increasing sensitivity for detecting minority mutations in MYD88 uses a locked nucleic acid oligo to block amplification of wild-type DNA in DNA isolated from patient FFPE tissue, bone marrow aspirate or peripheral blood samples during PCR while still allowing sequencing and visualization of the PCR product. Further improvement to the sensitivity may be achieved by using a uracil DNA-glycosylase treatment to remove sequence artifacts commonly found in formalin-fixed, paraffin-embedded tissue.


The present disclosure provides methods of detecting and determining the aggressiveness of prostate cancer. These methods can be used to determine whether or not a patient needs a biopsy as well as guide treatment selection.


Patent
NeoGenomics Laboratories | Date: 2013-09-11

An automated reader for reading fluorescence in-situ hybridization signals includes one or more computer processors for receiving a digitized FISH image and executing the steps of converting colors within the image to a hue value, separately for each color extracting quantitative values to detect the presence of signals corresponding to spots and applying a plurality of algorithms to extract features from the signals to determine cell shapes and segment cells within the FISH image. After recombining the signals, the extracted features for the colors learning machines are used to classify the spots according to the color and separate merged signals of classified spots that are in close proximity to each other within the image. The classified spots are counted to determine relative frequency of colors and a report is generated providing the number of classified spots of each color.


Patent
NeoGenomics Laboratories | Date: 2016-04-20

A method for detecting a low-occurrence mutation in isolated DNA adds a blocking probe to reagents during amplification of the isolated DNA. The blocking probe is an oligonucleotide complementary to wild-type DNA corresponding to the sample. The blocking probe spans a site of a suspected mutation within a region of interest in the isolated DNA. After amplification, fragments of the amplified DNA is sequenced using next generating sequencing and an output is generated to display the sequenced fragments. In some embodiments, the blocking probe is locked nucleic acid (LNA).

Loading NeoGenomics Laboratories collaborators
Loading NeoGenomics Laboratories collaborators